Cytokines as targets of immunotherapy in bacterial pneumonia

Journal of Laboratory and Clinical Medicine

Volumn 135, Issue 2, 2000, Pages 129-138

  Standiford, Theodore J ^a,b   Tsai, Wan C ^a   Mehrad, Borna ^a   Moore, Thomas A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CYTOKINE; GENE THERAPY; IMMUNITY; IMMUNOTHERAPY; LUNG;

EID: 0034141975     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2000.103196     Document Type: Article

References (42)

1. 1. Davies J. Inactivation of antibiotics and dissemination of resistance genes. Science 1994;264:375-82.
2. 2. Wunderink R. Ventilator-associated pneumonia. Clin Chest Med 1995;16:173-93.
3. 3. CDC. Update: Staphylococcus aureus with reduced susceptibility to vancomycin: United States. MMWR 1997;46:813-5.
4. 4. Toews GB, Gross GN, Pierce AK. The relationship of inoculum size to lung bacterial clearance and phagocytic cell response in mice. Am Rev Respir Dis 1979;120:559-66.
5. 5. Standiford TJ, Huffnagle GB. Cytokines in host defense against pneumonia. J Invest Med 1997;45:335-45.
6. 6. Laichalk LL, Kunkel SL, Strieter RM, Danforth JM, Bailie M, Standiford TJ. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infect Immun 1996;64:5211-8.
7. 7. Le J, Vilcek J. Tumor necrosis factor and interleukin-1: cytokines with multiple overlapping biological activities. Lab Invest 1987;56:234-48.
8. 8. Tracey KJ, Beutler B, Lowry SF, Cerami A. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.
9. 9. Oswald IP, Wynn TA, Sher A, James SL. Interleukin 10 inhibits macrophage microbicidal activity by blocking endogenous production of tumor necrosis factor-α required as a costimulatory factor for interferon-γ-induced activation. Proc Natl Acad Sci USA 1992;89:8676-80.
10. 10. Tan AM, Ferrante A, Goh DH, Robertson DM, Cripps AW. Activation of the neutrophil bactericidal activity for non typeable Haemophilus influenza by tumor necrosis factor and lymphotoxin. Pediatr Res 1995;37:155-9.
11. 11. Dehoux MS, Boutten A, Ostinelli J, Seta N, Dombret MC, Crestani B, et al. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994;150:710-6.
12. 12. Gosselin D, DeSanctis J, Boule M, Skamene E, Matouk C, Radzioch D. Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect Immun 1995;63:3272-8.
13. 13. Takashima K, Tateda K, Matsumoto T, Lizawa Y, Nakao M, Yamaguchi K. Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 1997;65:257-60.
14. 14. Kolls JK, Lei D, Nelson S, Summer WR, Greenberg S, Beutler B. Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J Infect Dis 1995;171: 570-5.
15. 15. Standiford TJ, Wilkowski JM, Sisson TH, Hattori N, Mehrad B, Bucknell KA, et al. Intrapulmonary tumor necrosis factor gene therapy increases bacterial clearance and survival in murine gram-negative bacterial pneumonia. Hum Gene Ther 1999;10:899-909.
16. 16. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Ann Rev Immunol 1997;15:675-05.
17. 17. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Laichalk LL, McGillicuddy D, et al. Neutralization of MIP-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia. J Infect Dis 1996;173:159-65.
18. 18. Murphy PM. Neutrophil receptors for interleukin-8 and CXC chemokines. Semin Hematol 1997;34:311-8.
19. 19. Tsai WC, Strieter RM, Wilkowski JM, Bucknell KA, Burdick MD, Lira SA, et al. Lung-specific transgenic expression of KC enhances resistance to Klebsiella pneumoniae in mice. J Immunol 1998;61:2435-40.
20. 20. Jenson W, Rose R, Wasserman A, Kalb T, Anton K, Remold H. In vitro activation of the antibacterial activity of human pulmonary macrophages by recombinant gamma interferon. J Infect Dis 1987;155:574-7.
21. 21. Rubins JB, Pomeroy C. Role of gamma interferon in the pathogenesis of bacteremic pneumococcal pneumonia. Infect Immun 1997;65:2975-7.
22. 22. Chehimi J, Trinchieri G. Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol 1994;14:149-59.
23. 23. Greenberger MJ, Kunkel SL, Strieter RM, Lukacs N, Bramson J, Gauldie J, et al. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 1996;157:3006-12.
24. 24. Howard M, O'Garra A, Ishida H, Malefyt RD, De Vries J. Biological properties of interleukin 10. J Clin Immunol 1992;12:239-47.
25. 25. Laichalk LL, Danforth JM, Standiford TJ. Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol Med Microbiol 1996;15:181-7.
26. 26. Rolph P, Nakoinz I, Sampson-Johannes A, Fong S, Lowe D, Min HY, et al. IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992;148:808-14.
27. 27. Kasama T, Strieter RM, Lukacs NW, Burdick MD, Kunkel SL. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994;152:3559-69.
28. 28. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177:1205-8.
29. 29. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL. Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995;155:2222-9.
30. 30. Greenberger MJ, Strieter RM, Kunkel SL, Danforth J, Goodman R, Standiford TJ. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995;155:722-9.
31. 31. van der Poll T, Marchant A, Keogh C, Goldman M, Lowry S. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996;174:994-1000.
32. 32. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Muller JM, et al. Monocyte deactivation: rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996; 22:S474-81.
33. 33. Munoz CJ, Carlet C, Fitting C. Misset B, Bleroit JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88: 1747-54.
34. 34. Wakefield CH, Cary PD, Foulds SJ, Monson RT, Guillou PJ. Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg 1993;80:205-9.
35. 35. Christou NV. Host-defense mechanisms in surgical patients: a correlative study of the delayed hypersensitivity skin-test response, granulocyte function and sepsis. Can J Surg 1985; 28:39-49.
36. 36. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Leptoutre A, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. JAMA 1995;274: 968-73.
37. 37. Randow F, Syrbe U, Meisel C, Krausch D, Zuckermann H, Platzer C, et al. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor β. J Exp Med 1995;181:1887-92.
38. 38. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 1996;64:4733-8.
39. 39. Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Strieter RM, Standiford TJ. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999;161:2435-40.
40. 40. Sawa T, Corry DB, Gropper MA, Ohara M, Kurahashi K, Wiener-Kronish JP. IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J Immunol 1997;159:2858-66.
41. 41. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med 1997;3:678-81.
42. 42. DeBoisblanc BP, Mason CM, Andresen J, Logan E, Bear MB, Johnson S, et al. Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community acquired pneumonia. Respir Med 1997;91:387-394.